StreetAlpha.app
Home › Stocks › FENC

Fennec Pharmaceuticals Inc. (FENC)

$13.09
▼ −2.68%
LAST CLOSE · NOV 20

Fennec Pharmaceuticals develops and sells PEDMARK, a sodium thiosulfate injection, from Research Triangle Park, North Carolina. It last closed at $13.09 on Nov 20, down 2.68% on the day. For the quarter ended Sep 2026, FENC reported EPS of $0.12 on revenue of $19.6M, with revenue up 57.3% from a year ago. Over its last 5 reports the stock moved an average of 2.2% the session after earnings. Over the last 12 months FENC insiders bought $0 of stock on the open market and sold $9.9M, according to SEC Form 4 filings.

AI Auto Pilots
Is FENC in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold FENC.

Key Stats

Last 12 months
Results
Revenue
$66.4M
+71.1% vs a year ago
Net income
$2.0M
3.1% margin
EPS (diluted)
$0.03
Operating margin
5.6%
$3.7M operating income
Valuation
Market cap
$462.1M
35.3M shares
P/E
436.3
Price over 12 month EPS
Price to sales
7.0
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$48.7M
At Sep 30
Shareholder equity
$49.2M
Shares outstanding
35.3M
At Nov 10
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2022: $1.5M$1.5MFY2022FY2023: $21.3M$21.3MFY2023FY2024: $47.5M$47.5MFY2024FY2025: $44.6M$44.6MFY2025

From FENC's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Last report
Mar 24
2026 · next date not set yet
Reported EPS
$0.12
Quarter ended Sep 2026
Year ago EPS
-$0.02
Same quarter last year
Revenue
$19.6M
+57.3% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.08Dec '24Mar 2025: -$0.04Mar '25Jun 2025: -$0.11Jun '25Sep 2025: -$0.02Sep '25Dec 2025: -$0.16Dec '25Mar 2026: $0.01Mar '26Jun 2026: $0.05Jun '26Sep 2026: $0.12Sep '26Latest $0.12
Revenue by quarter
Dec 2024: $7.9MDec '24Mar 2025: $8.8MMar '25Jun 2025: $9.7MJun '25Sep 2025: $12.5MSep '25Dec 2025: $13.8MDec '25Mar 2026: $15.1MMar '26Jun 2026: $17.9MJun '26Sep 2026: $19.6MSep '26Latest $19.6M
How FENC moved after its last 5 reports
Average move the session after a report ±2.2%
Mar 24, 2026After the close+2.5%
Mar 10, 2025After the close+4.8%
Mar 25, 2024After the close−1.0%
Nov 7, 2023Before the open+2.5%
Aug 4, 2023Time not announced+0.3%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on FENCStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on FENC
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on FENC

Technical Analysis

FENC · as of the Nov 20 close · updated each morning
Uptrend, nearing overbought

The stock is 14% above its 20 day and 18% above its 50 day average. It is 28% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 66), near overbought. The nearest support is the Pivot S1 at $12.64, and the nearest resistance the swing high (Aug 11) at $13.25.

Short trendBullish
Long trendBullish
MomentumStrong
StretchNear overbought
VolatilityHigh, 6.1%/day
Key levels
$13.8552 week high+5.8%
$13.55Pivot R1+3.5%
$13.25Swing high (Aug 11)+1.2%
$13.09Pivot+0.0%
$13.09Last close
$12.64Pivot S1−3.4%
$11.2220 day average−14.3%
$10.94100 day average−16.4%
$10.88Swing low (Aug 24)−16.9%
$10.7950 day average−17.6%
$9.49200 day average−27.5%
$5.6552 week low−56.8%
Indicators
RSI (14)65.99Strong, overbought above 70Neutral
MACD0.70Above its signal lineBullish
Stochastic88.0Near the top of its rangeOverbought
ADX (14)26.4Trending up
Williams %R-16.3Oversold below −80, overbought above −20Overbought
CCI (20)125.0Oversold below −100, overbought above 100Overbought
Rate of change+33.4%Change over 10 sessionsBullish
ATR (14)$0.80Typical daily range, 6.1% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for FENC

What happened before

See how FENC did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow FENC usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How FENC has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for FENCHow many large options trades hit FENC, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

FENC Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲57 buying vs 39 selling
  • ▲Held by funds +4.7 pts
  • ▲Funds holding +14
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding119105+13.3%
In funds' top 10440.0%
Held by funds50.9%46.2%+4.7 pts
New / increased22 / 3524 / 44−16.2%
Reduced / sold out31 / 818 / 8+50.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See FENC institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

FENC Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$9.9M16 sales · 6 insiders
22% of the selling was under pre-arranged trading plans.
2025-12 sold $7.6M2026-01 sold $78K2026-02 sold $80K2026-03 sold $84K2026-04 sold $69K2026-05 sold $129K2026-06 sold $94K2026-07 sold $100K2026-08 sold $1.1M2026-09 sold $281K2026-11 sold $240KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 13Marco Maria BrugheraDirectorSale plan20,000$12.00$240K
Sep 15Marco Maria BrugheraDirectorSale plan15,545$10.29$160K
Sep 1Rosty RaykovFormer DirectorSale plan10,000$12.11$121K
Aug 31Pierre Sargis SayadChief Medical OfficerSale12,000$12.18$146K
Aug 27Robert AndradeCFOSale plan75,000$11.78$884K
Aug 3Rosty RaykovFormer DirectorSale plan10,000$9.58$96K
Every insider buy and sale for FENC over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See FENC insider trades →

From SEC Form 4 filings by FENC's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether FENC is in one of them and how their past FENC trades turned out.

FENC in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered FENC in an article yet. Here's the latest on the wider market.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals is a pharmaceutical company based in Research Triangle Park, North Carolina. Its main product is PEDMARK, a sodium thiosulfate injection that the company develops and commercializes. The company relies on patents and licensed intellectual property to protect PEDMARK from competing generic versions. It works with licensors and collaborators on its technologies and product.

Headquarters
Research Triangle Park, NC